Effects of relugolix combination therapy on bone mineral density through 2 years in women with heavy menstrual bleeding associated with uterine fibroids

Relugolix 40 mg is a non-peptide gonadotropin-releasing hormone receptor antagonist being developed for use in combination with estradiol 1 mg and norethindrone acetate 0.5 mg (relugolix combination therapy; Rel-CT) to treat heavy menstrual bleeding (HMB) associated with uterine fibroids (UF). The rationale for combination therapy is to mitigate anticipated hypoestrogenic effects with relugolix monotherapy, including bone loss. Rel-CT preserved bone mineral density (BMD) in the pivotal LIBERTY 1/2 trials and Long-Term Extension (LTE) study.
Source: Fertility and Sterility - Category: Reproduction Medicine Authors: Source Type: research